Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter

Reuters2026/08/14 20:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Apimeds posted a net loss of USD 20.17 million for the quarter ended June 30, 2026, widening from USD 2.66 million.
Loss per share widened to USD 11.77 from USD 2.57.
Other expense swung to USD 13.89 million from other income of USD 1,711, driven by a USD 13.18 million unrealized digital-asset loss.
General and administrative costs jumped to USD 5.32 million from USD 2.01 million, on settlement-related fees and transaction costs.
Digital assets had a fair value of USD 116.74 million, representing 89% of total assets, with earnings volatility tied to fair-value changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090120), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter

You may also like

Crypto prices